HIE News Round Up: MU and High Cost of Care; MIPS Participation Increases; and Industry Collaboration Improves Health Data Inaccuracies
Welcome to the Health Information Exchange Weekly News Round Up from RosettaHealth. Each week, we will provide you with a summary of all the actionable news that hospitals, HIT vendors, ACOs, and population health providers need to be smart and effective when it comes to health information exchange.
Senator Cassidy Blames Meaningful Use for High Cost of Care
Reducing administrative burden associated with federal regulation — particularly the meaningful use program — may help to significantly cut unnecessary healthcare costs, according to Senator Bill Cassidy (R-LA).
Catching Up With Recent Moves In EHR, Interoperability Initiatives
Apple, Allscripts, athenahealth, Cerner and others made noteworthy moves in the last few weeks. Learn more here.
Quality Payment Program Year 1 Participation Exceeds 90 Percent
Over 90 percent of eligible clinicians participated in the Merit-Based Incentive Payment System (MIPS) during the first year of the Quality Payment Program (QPP), according to CMS.
Opening Health IT, EHR Market to Spur Improved Clinical Productivity
Widespread EHR adoption has so far produced only modest improvements in clinical productivity and efficiency, but two doctors anticipate increased competition, diversity, and growth in the health IT and EHR market.
Industry Collaboration Can Improve Healthcare Data Inaccuracies
Broad collaboration between numerous healthcare stakeholders is crucial for developing an efficient and sustainable system that can cut down on healthcare data inaccuracies, according to a new report.
Poll: Half Of Older Adults Say ‘No Thanks’ To Patient Portals
A new poll suggests that many older adults still aren’t using online systems to communicate with the doctors and other health care providers they rely on—despite the widespread availability of such systems.
FDA to Collect Patient Experience Data
The Food and Drug Administration (FDA) has embarked on an effort to include “meaningful” patient experience data in its decisions on new drug approvals and post-marketing surveillance.